AbCellera Biologics (ABCL) Receivables (2020 - 2026)
AbCellera Biologics (ABCL) recorded Receivables of $38.42 million in Q2 2026, down 45.1% from $70.01 million a year earlier and down 1.9% from the prior quarter.
Powered by 
Analysis
AbCellera Biologics (ABCL) Receivables (2020 - 2026) Analysis & Trends
At the end of FY2025, AbCellera Biologics reported Receivables of $58.29 million, up 73.4% from FY2024.
- Annual Receivables has a five-year compound annual growth rate of -32.8% (FY2020 to FY2025).
- Across earlier years, Receivables came in at $33.62 million in FY2024 (+9.9%), $30.59 million in FY2023 (-20.7%), $38.59 million in FY2022 (-76.0%) and $160.58 million in FY2021 (-62.3%).
- The Q2 2026 figure is the lowest quarterly Receivables since Q4 2024.
- On a year-over-year basis, Receivables rose in five of the last eight quarters, with growth averaging 36.1%.
- Peak year-over-year performance for Receivables in the last five years was growth of 142.9% in Q3 2022, against a decline of 94.0% in Q1 2023 at the low end.
- Per Business Quant, the preceding three quarters came in at $39.16 million (Q1 2026), $58.29 million (Q4 2025) and $71.25 million (Q3 2025).
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Receivables (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,261.99 Bn | 1,235.61 Bn | 20.46 Bn | 25.23 Bn |
| 2 | Johnson & Johnson | 678.93 Bn | 598.79 Bn | 17.30 Bn | 18.99 Bn |
| 3 | AbbVie | 518.29 Bn | 486.30 Bn | 13.12 Bn | 13.51 Bn |
| 4 | Merck | 365.98 Bn | 328.92 Bn | 13.19 Bn | 12.74 Bn |
| 5 | Novartis Ag | 316.85 Bn | 290.09 Bn | - | - |
| 6 | Astrazeneca | 293.40 Bn | 267.29 Bn | 13.26 Bn | 16.16 Bn |
| 7 | Amgen | 251.78 Bn | 203.43 Bn | 7.58 Bn | 10.35 Bn |
| 8 | Gilead Sciences | 210.61 Bn | 185.71 Bn | 6.73 Bn | 5.01 Bn |
| 9 | Pfizer | 166.87 Bn | 114.23 Bn | 12.56 Bn | 14.19 Bn |
| 10 | AbCellera Biologics | 3.83 Bn | 3.29 Bn | - | 38.42 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 38.42 Mn |
| Mar 31, 2026 | 39.16 Mn |
| Dec 31, 2025 | 58.29 Mn |
| Sep 30, 2025 | 71.25 Mn |
| Jun 30, 2025 | 70.01 Mn |
| Mar 31, 2025 | 63.61 Mn |
| Dec 31, 2024 | 33.62 Mn |
| Sep 30, 2024 | 31.37 Mn |
| Jun 30, 2024 | 36.14 Mn |
| Mar 31, 2024 | 34.42 Mn |
| Dec 31, 2023 | 30.59 Mn |
| Sep 30, 2023 | 37.45 Mn |
| Jun 30, 2023 | 45.68 Mn |
| Mar 31, 2023 | 20.00 Mn |
| Dec 31, 2022 | 38.59 Mn |
| Sep 30, 2022 | 105.96 Mn |
| Jun 30, 2022 | 52.80 Mn |
| Mar 31, 2022 | 334.40 Mn |
| Dec 31, 2021 | 160.58 Mn |
| Sep 30, 2021 | 43.63 Mn |
API Access
AbCellera Biologics Receivables API
Pull this series into your own models, spreadsheets and apps with the Business Quant
Historical Metrics API. The request below matches the chart above — change the
frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.
https://data.businessquant.com/historic?slug=receivables&ticker=ABCL&period=max&api_key=YOUR_API_KEYimport requests
url = "https://data.businessquant.com/historic"
params = {"slug": "receivables", "ticker": "ABCL", "period": "max", "api_key": "YOUR_API_KEY"}
data = requests.get(url, params=params).json()const res = await fetch("https://data.businessquant.com/historic?slug=receivables&ticker=ABCL&period=max&api_key=YOUR_API_KEY");
const data = await res.json();